9th Annual Biomarkers Congress

View Profile


Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors
1. 2011 Amylin and GLP-1-based therapies for the treatment of diabetes. In: UpToDate, UpToDate, Wellesley, MA, 2005-2007.
2. 2010 Lack of association between thiazolidinediones and macular edema in type 2 diabetes: The ACCORD Eye Study Archives of Ophthalmology, in press, expected publication January 2010.
3. 2010 Univariate and bivariate linkage analysis identifies pleiotropic loci underlying lipid levels and type 2 diabetes risk Ann Hum Genet. 74(4):308-15, 2010
4. 2010 Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes N Engl J Med. 2010 PubMed PMID: 20587585
5. 2010 Association of cardiac and vascular changes with ambient PM2.5 in diabetic individuals Part Fibre Toxicol. 2010 Jun 2;7:14. PubMed PMID: 20525188
6. 2010 Action to Control Cardiovascular Risk in Diabetes Investigators. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial Diabetes Care. 33(5):983-90, 2010
7. 2010 Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis Lancet. 375(9723):1365-74, 2010
8. 2010 Type 2 diabetes mellitus Williams Textbook of Endocrinology, 12th ed Elsevier Science, Philadelphia, PA.
9. 2010 Liraglutide Effect Action in Diabetes-6 Study Group. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care. 33(6):1300-3, 2010
10. 2010 Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med. 362(17):1563-74, 2010
11. 2010 Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes N Engl J Med. 363(3):233-244, 2010
12. 2010 Effects of intensive bloodpressure control in type 2 diabetes mellitus N Engl J Med. 362(17):1575-85,2010
13. 2010 DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks Diabetes Care. 33(6):1255-61, 2010
14. 2010 Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy Arch Ophthalmol. 128(3):312-8, 2010
15. 2010 Effect of valsartan on the incidence of diabetes and cardiovascular events N Engl J Med. 362(16):1477-90, 2010
16. 2010 Effect of nateglinide on the incidence of diabetes and cardiovascular events N Engl J Med. 362(16):1463-76, 2010
17. 2010 Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits Diabetes Care. 2010 Feb;33(2):428-33
18. 2010 The association between symptomatic, Severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study BMJ. 2010 Jan 8 on-line. PMID: 20061358
19. 2010 Type 1 diabetes mellitus Williams Textbook of Endocrinology, 12th ed .Elsevier Science, Philadelphia, PA.
20. 2010 The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study BMJ. 2010 Jan 8 on line
21. 2010 Management of type 2 diabetes mellitus Endocrinology, 6 th edition. Elsevier, Philadelphia, PA.
22. 2009 Rationale, design and methods of the HEALTHY study physical education intervention component International Journal of Obesity. 2009 33 (suppl 4):37-43
23. 2009 Rationale, design and methods of the HEALTHY study behavior intervention component International Journal of Obesity. 2009 33 (suppl 4):44-51
24. 2009 Social marketing-based communications to integrate and support the HEALTHY study intervention International Journal of Obesity. 2009 33 (suppl 4):52-59
25. 2009 Rationale, design and methods for process evaluation in the HEALTHY study International Journal of Obesity. 2009 33 (suppl 4):60-67
26. 2009 Modifying middle school physical education: piloting strategies to increase physical activity Pediatric Exercise Science. 2009, 21, 171-185.
27. 2009 Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32:193-203. (Simultaneously published as Diabetologia. 2009; 52:17-30. )
28. 2009 Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009; 32:187-92. (Simultaneously published as Circulation 2009; 119:351-7 and J Am Coll Cardiol. 2009; 53:298-304.)
29. 2009 How do we define cure of diabetes? Diabetes Care 32:2133-5, 2009.
30. 2009 Pre-diabetes and the prevention of diabetes Educational Review Manual in Endocrinology, Diabetes and Metabolism, Focus: Diabetes, 3rd ed . Castle Connolly Graduate Medical Publishing, New York, NY. Pp. 289-298, 2009.
31. 2009 Can we become victims of our own success? Diabetes Care 32:2140-1, 2009.
32. 2009 Risk factors for type 2 diabetes in a sixth- grade multiracial cohort: the HEALTHY study Diabetes Care. 2009; 32:953-5
33. 2009 Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD) Diabetes Care 2009; 32: 1224–1230
34. 2009 Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) Lancet. 2009; 374(9683):39-47
35. 2009 Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial JAMA. 2009; 301:1547-55
36. 2009 Boosting enrollment in neurology trials with Local Identification and Outreach Networks (LIONs) Neurology. 2009; 72(15):1345-51
37. 2009 DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes Diabetes Care. 2009; 32:1007-13
38. 2009 Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes J Clin Endocrinol Metab. 2009; 94:1689-94
39. 2009 How do we define cure of diabetes? Diabetes Care. 2009; 32:2133-5
40. 2009 Constructing common cohorts from trials with overlapping eligibility criteria: implications for comparing effect sizes between trials Clin Trials 6:41629,2009
41. 2009 Clinical experience with continuous glucose monitoring in adults Diabetes Technol Ther. 2009;11 Suppl 1:S93-S103
42. 2009 Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP) Diabetes Metab Res Rev. 2009; 25:558-65
43. 2009 Intensive glucose control and macrovascular outcomes in type 2 diabetes Diabetologia. 2009 Aug 5. Epub.
44. 2009 The HEALTHY study: introduction International Journal of Obesity. 2009 33 (suppl 4):1-2
45. 2009 HEALTHY study rationale, design and methods: moderating risk of type 2 diabetes in multi-ethnic middle school students International Journal of Obesity. 2009 33 (suppl 4):4-20
46. 2009 Diabetes and cardiovascular disease – the impact of glycemic control Educational Review Manual in Endocrinology, Diabetes and Metabolism, Focus: Diabetes, 3rd ed. Castle Connolly Graduate Medical Publishing, New York, NY. Pp. 229-242, 2009.
47. 2009 Diabetes standards of care The Uncomplicated Guide to Diabetes Complications, 3rd edition. American Diabetes Association, Alexandria, VA. pp. 16-25, 2009.
48. 2009 Recruitment and retention strategies and methods in the HEALTHY study International Journal of Obesity. 2009 33 (suppl 4):21-28.
49. 2009 Rationale, design and methods of the HEALTHY study nutrition intervention component International Journal of Obesity. 2009 33 (suppl 4):29-36
50. 2008 Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study Lancet. 2008; 372:1240-50
51. 2008 Development and validation of the Diabetes Numeracy Test (DNT). BMC Health Serv Res. 2008; 8:96
52. 2008 Impact of portion-size control for school a la carte items: changes in kilocalories and macronutrients purchased by middle school students. J Am Diet Assoc. 2008; 108:140-4.
53. 2008 Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J. 2008; 155:26-32
54. 2008 Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. Am Heart J. 2008; 155:215-23
55. 2008 Type 2 diabetes mellitus Williams Textbook of Endocrinology, 11th ed . Elsevier Science, Philadelphia, PA. pp. 1329-89, 2008.
56. 2008 Type 1 diabetes mellitus Williams Textbook of Endocrinology, 11th ed . Elsevier Science, Philadelphia, PA. pp. 1391-1416, 2008
57. 2008 Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. . Curr Med Res Opin. 2008; 24:275-86
58. 2008 Are prescribing patterns of antidiabetic medications influenced by fears of litigation? Nat Clin Pract Endocrinol Metab. 2008; 4:440-1.
59. 2008 Association of Family Medicine Residency Directors. Frontline: diabetes--supplementing education and quality improvement in family medicine residency training. Ann Fam Med. 2008;6:88-9.
60. 2008 A dead heat: target normal glucose levels in the intensive care unit-but with caution. Diabetologia. 51(6):909-10, 2008.
61. 2008 Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial Am Heart J. 2008 Oct;156(4):623-32
62. 2008 Endothelial dysfunction: associations with exposure to ambient fine particles in diabetic individuals Environ Health Perspect. 2008; 116:1666-74
63. 2008 Effects of intensive glucose lowering in type 2 diabetes N Engl J Med. 2008; 358:2545-59
64. 2007 A comparison of lipid and lipoprotein measurements in the fasting and nonfasting states in patients with type 2 diabetes. Current Medical Research and Opinion 2007; 23:2689-2695.
65. 2007 Glucose measurement: confounding issues in setting targets for inpatient management. Diabetes Care 30: 403-409, 2007.
66. 2007 Consensus statement on the worldwide standardization of the hemoglobin A1C measurement. Simultaneously published: Diabetes Care 30:2399-2400, 2007, Clinical Chemistry 53:1562-1564, 2007
67. 2007 Response to Dr. Nicolucci and co-workers. Diabetes Care 30:E---, 2007. DOI: 10.2337/dc07-0463.
68. 2007 Can the American Diabetes Association have an impact on preventing and treating the diabetes epidemic in 2007-2008? An interview with the incoming president. MedGenMed. 2007;9:9.
69. 2007 Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99[suppl]:44i-55i
70. 2007 Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99[suppl]:56i-67i
71. 2007 Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Am J Cardiol 2007;99[suppl]:68i-79i
72. 2007 Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99[suppl]:80i-89i
73. 2007 Health-related quality of life and cost-effectiveness components of the Action for Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design. Am J Cardiol 2007;99[suppl]:90i-102i
74. 2007 Rationale, design and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-Eye). Am J Cardiol 2007;99[suppl]:103i-111i
75. 2007 The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design and methods. Am J Cardiol 2007;99[suppl]:112i-122i
76. 2007 Improving the school food environment: results from a pilot study in middle schools. J Am Diet Assoc. 107:484-9, 2007
77. 2007 Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clinical Therapeutics 29:139-53, 2007
78. 2007 Detection of Ischemia in Asymptomatic Diabetics (DIAD) Investigators. Resolution of asymptomatic myocardial ischemia in patients with type 2 diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study. Diabetes Care. 2007; 30:2892-8.
79. 2007 Resolution of asymptomatic myocardial ischemia in patients with type 2 diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study Diabetes Care. 2007; 30:2892-8
80. 2007 Primary prevention of cardiovascular diseases in people with diabetes: a joint statement and recommendations from the American Diabetes Association and the American Heart Association. Diabetes Care 30:167-172, 2007 and Circulation 115:114-26, 2007.
81. 2007 Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2007; 30:2458-64
82. 2007 Introduction (to the ACCORD Supplement) Am J Cardiol 2007;99[suppl]:1i-3i
83. 2007 Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: Current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99[suppl]:4i-20i
84. 2007 Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and methods. Am J Cardiol 2007;99[suppl]:21i-33i
85. 2007 Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99[suppl]:34i-43i
86. 2006 The metabolic syndrome: Time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes - Response to Citrome et al., Giugliano and Esposito, Cheta, and Psaty et al. Diabetes Care 29:177-178, 2006.
87. 2006 Management of hyperglycemia in type 2 diabetes mellitus: A consensus algorithm for the initiation and adjustment of therapy. Simultaneously published: Diabetes Care 29:1963-1972, 2006 and Diabetologia 49:1711-21, 2006.
88. 2006 Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN). Diabetes Care 29: 1478-1485, 2006
89. 2006 GENNID: A shareable repository of genetic material for the study of type 2 diabetes. Resubmitted. 2006
90. 2006 A practical approach to the management of type 2 diabetes in the context of cardiovascular risk. Pri-Med in Practice. Primed, Boston, MA, 2006. 2 pages
91. 2006 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 29:1214-9, 2006
92. 2006 Consensus Development Conference on Pramlintide in the Management of Type 1 and Type 2 Diabetes. The Diabetes Education Group, Lakeville, CT, 2006. 16 pages.
93. 2006 Scope of the problem: The diabetes-metabolic epidemic Clinical Diabetes: Translating Research into Practice. Saunders, Philadelphia, PA. pp. 1-5, 2006.
94. 2006 Prevalence of abnormal lipid and blood pressure values among an ethnically diverse population of eighth-grade adolescents and screening implications. Pediatrics 117:2065-73, 2006
95. 2005 A real-world approach to insulin therapy in primary care practice. Clinical Diabetes 23:78-86, 2005.
96. 2005 Management of Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State in Adults. Scherer Clinical Communication, 2005. 24 pages.
97. 2005 The metabolic syndrome. Lancet 366:1921-2, 2005.
98. 2005 Prevention of cardiovascular outcomes in type 2 diabetes mellitus: trials on the horizon. Endocrinol Metab Clin North Am. 34:221-35, 2005.
99. 2005 Glucagon-like peptide 1-based therapies for type 2 diabetes: A focus on exenatide. Clinical Diabetes 23:56-62, 2005.
100. 2005 Recommendations for management of diabetes during Ramadan. Diabetes Care 28:2305-11, 2005.
101. 2005 The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Simultaneously publishedL Diabetes Care 28:2289-304, 2005 and Diabetologia 48:1684-99, 2005.
102. 2005 Prevention of cardiovascular outcomes in type 2 diabetes mellitus: Trials on the horizon. Cardiology Clinics 23:211-220, 2005.
103. 2005 Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications. Br J Psychiatry Suppl. 47:S94-101, 2004. Erratum Br J Psychiatry 186:449, 2005.
104. 2005 Analysis of quantitative lipid traits in the genetics of NIDDM (GENNID) study. Diabetes 54:3007-14, 2005
105. 2005 Meta-analysis of genome-wide linkage studies for quantitative lipid traits in African Americans. Hum Mol Genet 14:3955-62, 2005
106. 2005 Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care 28:337-442, 2005
107. 2005 A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28:1547-54, 2005
108. 2005 Muraglitazar, a dual (alpha/gamma) PPAR activator: A randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin Ther. 27:1181-95, 2005
109. 2005 Ketoacidosis, HONKC and hypoglycemia Principles of Critical Care Medicine, 3rd Edition ,McGraw Hill, New York, NY. 1209-17, 2005.
110. 2005 Diabetes mellitus in adults Conn’s Current Therapy, 2005. Saunders, Philadelphia, PA. pp. 661-670, 2005
111. 2005 Management of type 2 diabetes mellitus Endocrinology, 5th edition . Elsevier, Philadelphia, PA. pp 1231-48, 2005
112. 2004 Detection of Silent Myocardial Ischemia in Asymptomatic Diabetic Subjects: The DIAD study. Diabetes Care 27: 1954-61, 2004.
113. 2004 Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. American Journal of Nephrology 24:32-40, 2004.
114. 2004 Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes. Current Medical Research and Opinion 20:215-223, 2004.
115. 2004 Rationale for standards of care. The Cadre Handbook of Diabetes Management . Medical Information Press, New York, NY, 2004. pp. 29-51.
116. 2004 The ACCORD Trial: A Multidisciplinary Approach to Control Cardiovascular Risk in Type 2 Diabetes Mellitus. Practical Diabetology 23 (4): 6-11, 2004.
117. 2004 The effects of oral antihyperglycemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 6:133-56, 2004.
118. 2004 Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27:2628-35, 2004
119. 2004 Consensus development conference on antipsychotic drugs and obesity and diabetes. Obesity Research 12:362-368, 2004.
120. 2003 Statin treatment in diabetes mellitus. Clinical Diabetes 21:168-172, 2003.
121. 2003 Type 1 diabetes mellitus Williams Textbook of Endocrinology, 10th ed .Elsevier Science. pp. 1485-1508, 2003.
122. 2003 CME Circle: Pathways Leading to Diabetic Microvascular Complications and the Latest Clinical Therapies. Medscape Diabetes and Endocrinology. Posted: 9/22/03. Available at: http://www.medscape.com/viewprogram/2636.
123. 2003 Ask the Expert: Waiting for a Change in A1C. Medscape Diabetes and Endocrinology. Posted: 9/9/03. Available at: http://www.medscape.com/viewarticle/460876.
124. 2003 Glitazones and heart failure: critical appraisal for the clinician. Circulation. 108(8):e57, 2003
125. 2003 Ask the Expert: A Case of Malingering? Medscape Diabetes and Endocrinology. Posted:3/14/03. Available at: http://www.medscape.com/viewprogram/595.
126. 2003 Ask the Expert: The Lowest Glucose of the Day. Medscape Diabetes and Endocrinology. Posted: 3/11/03. Available at: http://www.medscape.com/viewarticle/450197.
127. 2003 Type 2 diabetes mellitus Williams Textbook of Endocrinology, 10th ed . Elsevier Science, Philadelphia, PA. pp. 1427-1483, 2003.
128. 2003 Evolution in the American Diabetes Association Standards of Care Clinical Diabetes 21:24-26, 2003.
129. 2003 Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160-7, 2003.
130. 2003 Should postprandial glucose be routinely measured and treated to a particular target? No! Diabetes Care 26:1615-8, 2003.
131. 2003 Lipid changes associated with diabetes therapy. Practical Diabetology 22(1):24-9, 2003.
132. 2003 Patient Information: Protect your heart, protect your life. Clinical Diabetes, 21: 173, 2003.
133. 2003 Practical Pointers: Statin treatment in diabetes mellitus. Clinical Diabetes, 21: 168-72, 2003.
134. 2003 The insulin resistance syndrome and coronary artery disease. Coronary Artery Disease 14:335-48, 2003.
135. 2003 Serum 1,5-anhydroglucitol (GlycoMark ): a short-term glycemic marker. Diabetes Technology and Therapeutics 5:355-63, 2003.
136. 2003 The prevention or delay of type 2 diabetes. Diabetes Care 26 (Suppl 1):s62-9, 2003.
137. 2003 Diabetes mellitus and its complications Netter’s Internal Medicine. Icon Learning Systems LLC, Teterboro, NJ. pp. 184-194, 2003.
138. 2003 Should postprandial glucose be routinely measured and treated to a particular target? Connecting the two sides of the debate. Diabetes Care. 26(9):2700-1, 2003.
139. 2003 Further evidence for a type 2 diabetes susceptibility locus on chromosome 11q. Genet Epidemiol 24:240-2, 2003.
140. 2003 A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. Journal of Clinical Epidemiology 56:164-70, 2003.
141. 2003 Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 88:3082-9, 2003.
142. 2003 Evolution in the ADA Standards of Care. Clinical Diabetes 21: 24-6, 2003.
143. 2003 CME Circle: Enhancing Outcomes by Addressing Critical Challenges in the Treatment of Schizophrenia. Medscape Psychiatry and Mental Health. Posted: 9/26/03. Available at: http://www.medscape.com/viewprogram/2632.
144. 2002 Diabetic genetics: a complex picture. Consultant 42:452, 2002.
145. 2002 Consensus statement: the prevention or delay of type 2 diabetes. Diabetes Care 25:742-749, 2002.
146. 2002 What we think and what we know. Diabetes Care 25:1876-8, 2002.
147. 2002 Diabetes Treatment: Focus on Postprandial Glucose. In: Postprandial Hyperglycemia in Type Diabetes. Postgraduate Institute for Medicine, 2002 (3 pages).
148. 2002 Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial. Archives of Internal Medicine 162:1568-76, 2002.
149. 2002 Physician attitudes and practices and patient awareness of the cardiovascular complications of diabetes. Journal of the American College of Cardiology 40:1877-81, 2002.
150. 2002 Genetics of NIDDM. Genomewide search for type 2 diabetes susceptibility genes in four American populations. Am J Hum Genet 66:1871-81, 2000. Erratum Am J Hum Genet 70:284, 2002.
151. 2002 Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S. Diabetes 51:2170-8, 2002.
152. 2002 The Basics of Continuous Subcutaneous Insulin Infusion Therapy. HealthAnswers, Inc. 2002.
153. 2002 Diabetes tactics: Aggressive treatment of type 2 diabetes. Current Practice (The official publication of the Council for the Advancement of Diabetes Research and Education) 1(2):4-6, 2002.
154. 2002 Metabolic side effects of antipsychotics: focus on hyperglycemia and diabetes. Journal of Clinical Psychiatry 63(supplement 4): 37-41, 2002.
155. 2002 Diabetic Ketoacidosis in the Adult Patient. HealthAnswers, Inc. 2002
156. 2002 Recent findings: five epidemiological studies who comparable rates of diabetes among antipsychotic agents. In: Clinical Perspectives in Psychiatry. Medical Education Network, New York, 2002
157. 2002 Metabolic Side Effects: Focus on Hyperglycemia and Diabetes. JCP Visuals. Physicians Postgraduate Press, Inc., 2002 (2 pages).
158. 2002 Amylin replacement with pramlintide in type 1 and type 2 diabetes: A physiological approach to overcome barriers with insulin therapy. Clinical Diabetes 20:137-144, 2002.
159. 2001 Consensus statement: postprandial blood glucose. Diabetes Care 24:775-778, 2001.
160. 2001 Ask the Expert: Rotating Injection Sites. Posted: 10/04/01. Available at: http://www.medscape.com/viewarticle/412395.
161. 2001 Ask the Expert: Agents Interfering with Home Testing of Blood Glucose. Medscape Diabetes and Endocrinology. Posted: 9/25/01. Available at: http://www.medscape.com/viewarticle/412368.
162. 2001 Insulin analogues. Current Opinion in Endocrinology & Diabetes 8:95-100, 2001.
163. 2001 High insulin levels: target for treatment? Consultant 41: 502,5, 2001.
164. 2001 New treatment strategies for type 2 diabetes: Where are we now and where are we going?. In: Current Diabetes Care: The evolving role in the pharmacist and emerging treatment strategies. BioScience Communications, New York, NY, 2001. (7 pages)
165. 2001 Ask the Expert: Alpha-glucosidase Inhibitors for Type 1 Diabetes. Medscape Diabetes and Endocrinology. Posted: 11/13/01. Available at: http://www.medscape.com/viewarticle/412376.
166. 2000 Thiazolidinediones in the treatment of type 2 diabetes: a clinician’s perspective. American Journal of Managed Care 6(suppl 13):s710-7, 2000.
167. 2000 Pioglitazone in the treatment of type 2 diabetes mellitus: U.S. clinical experience. Experimental and Clinical Endocrinology & Diabetes (suppl 2) 108: 250-255, 2000.
168. 2000 Clinical Update: Diabetes Management in the 21st Century: Multiple Therapeutic Options for Achieving Glycemic Control. Medscape Diabetes and Endocrinology. Posted: 12/13/2000. Available at http://www.medscape.com/viewprogram/595.
169. 2000 Insulin glargine (HOE901): first responsibilities: understanding the data and ensuring safety. Diabetes Care. 23:576-8, 2000.
170. 2000 Insulin Resistance Syndrome Blackwell Science, Oxford, UK. pp. 7-10, 2000
171. 2000 American Pharmaceutical Association New Product Bulletin. Lantus (insulin glargine). John R. White; Members: Janelle F. Bagsall, John B. Buse, Betsy A. Carlisle.
172. 2000 Progressive use of medical therapies in type 2 diabetes. Diabetes Spectrum 13(4): 211-220, 2000.
173. 2000 Combining insulin and oral agents. American Journal of Medicine 108 (Supplement 6a): 23-32, 2000.
174. 1999 The Patient with Diabetes Management of Office Emergencies ,McGraw Hill, New York. pp. 73-95, 1999
175. 1999 Diabetic Emergencies. Acute Glycemic Control. Patterns of Care: Guidelines for Diabetes Care. Patterns of Care Task Force. The North Carolina Diabetes Advisory Council. Raleigh, NC. 1999, 11 pages.
176. 1999 Making Nutrition Work in the Management of Type 2 Diabetes: A Guide for Patients. Bayer Corporation, West Haven, CT. 1999, 13 pages.
177. 1999 Insulin Resistance: Role in the Clinical Management of Diabetes. Pharmedica Communications, Killingworth, CT. 1999, 24 pages.
178. 1999 The use of insulin alone and in combination with oral agents in type 2 diabetes. Primary Care Clinics in Office Practice 26: 931-50, 1999.
179. 1999 Consensus development conference on diabetic foot wound care. Simultaneously published Diabetes Care 22:1354-60, 1999 and Journal of the American Podiatric Medical Association 89:475-483, 1999.
180. 1999 Overview of current therapeutic options in type 2 diabetes. Rationale for combining oral agents with insulin therapy. Diabetes Care 22(suppl. 3): c65-70, 1999.
181. 1999 Making Nutrition Work in the Management of Type 2 Diabetes: A Guide for Diabetes Care Providers. Bayer Corporation, West Haven, CT. 1999. 38 pages.
182. 1999 Advances in Diabetes Treatment - Implications for Lipid Management. Lipid Nurse Task Force Newsletter, Milwaukee, WI. 1999, 4 pages.
183. 1999 Diabetes Management. Long Term Glycemic Control. Patterns of Care: Guidelines for Diabetes Care. Patterns of Care Taks Force. The North Carolina Diabetes Advisory Council. Raleigh, NC. 1999, 11 pages.
184. 1999 Myths Regarding Diabetes Care and Coronary Disease. Lipid Nurse Task Force Newsletter, Milwaukee, WI. 1999, 4 pages.
185. 1998 Diabetic ketoacidosis, hyperglycemic hyperosmolar nonketotic coma, and hypoglycemia Principles of Critical Care Medicine, 2nd Edition. McGraw Hill, New York. pp. 1183-1193, 1998.
186. 1998 Review of Ralph DeFronzo's Current Therapy of Diabetes Mellitus. Annals of Internal Medicine. 128:331-2, 1998.
187. 1998 The PROTECT study: final results of a large multicenter postmarketing study in patients with type 2 diabetes. Clinical Therapeutics 20(2):257-69, 1998.
188. 1998 Troglitazone use in insulin-treated type 2 diabetic patients. Diabetes Care 21(9):1455-61, 1998.
189. 1998 Monitoring Diabetes Therapy for Diabetes Mellitus and Related Disorders, 3rd ed . American Diabetes Association, Alexandria, VA. Pp 109-117, 1998.
190. 1998 The role of medical nutrition therapy in type 2 diabetes. Mediguide to Diabetes (Whitehouse FW, ed.). Lawrence DellaCorte Publications, Inc, New York, NY. 4(5):1-6, 1998.
191. 1998 Medical Management of Type 2 Diabetes American Diabetes Association, Alexandria, VA. 1998. 141 pages.
192. 1998 Management of glycemia in type 2 diabetes. Clinical Cornerstone. 1(3):39-57, 1998.
193. 1998 The case for a role of postprandial glucose monitoring in diabetes management. Journal of Family Practice 47(suppl.):s29-s36, 1998.
194. 1998 Is there a role for cardiovascular risk factor reduction in pre-menopausal woman with diabetes? Lipid Nurse Task Force Newsletter, Milwaukee, WI. 1998, 3 pages.
195. 1997 Clinical Case Studies in Diabetes. Pearls and Pitfalls. A Focus on NIDDM. Clinical Communications, Greenwich, CT. 1997 (33 pages).
196. 1997 Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 46:433-9, 1997.
197. 1997 Postprandial hyperglycemia: Implications for NIDDM. Boston. Pharmedica Press, Killingworth, CT. December, 1997. (12 pages)
198. 1997 Postprandial hyperglycemia: Implications for NIDDM. Atlanta. Pharmedica Press, Killingworth, CT. December, 1997. (12 pages)
199. 1997 Postprandial hyperglycemia: Implications for NIDDM. Chicago. Pharmedica Press, Killingworth, CT. December, 1997. (12 pages)
200. 1997 Postprandial hyperglycemia: Implications for NIDDM. Dallas. Pharmedica Press, Killingworth, CT. December, 1997. (12 pages)
201. 1997 Postprandial hyperglycemia: Implications for NIDDM. San Fransisco. Pharmedica Press, Killingworth, CT. December, 1997. (12 pages)
202. 1997 Clinical Case Studies in Diabetes. Pearls and Pitfalls. A Focus on NIDDM for the Specialist. Clinical Communications, Greenwich, CT. 1997 (33 pages).
203. 1997 Review of Ralph DeFronzo's Current Therapy of Diabetes Mellitus. Doody's Review Service (on-line). Available at http://www.doody.com. December 1, 1997.
204. 1997 Diabetic Ketoacidosis Conn's Current Therapy 1997 . W.B. Saunders Co., Philadelphia, PA. pp. 553-7, 1997.
205. 1997 Management of Type II Diabetes Manual of Clinical Problems in Adult Ambulatory Care, 3rd ed
206. 1997 Management of Complications of Diabetes Manual of Clinical Problems in Adult Ambulatory Care, 3rd ed . Lippincott-Raven Publishers, Philadelphia. pp. 371-5, 1997.
207. 1996 The Pancreas Handbook of Endocrinology, 3nd ed . CRC Press, Boca Raton. pp 297-314, 1996.
208. 1996 A resource for mapping the genes that cause NIDDM. Diabetes Care 19:864-72, 1996.
209. 1996 Peripheral blood mononuclear cell dihydropyrimidine dehydrogenase activity in volunteers with and without diabetes mellitus. Cancer Chemother Pharmacol 37:569-73, 1996.
210. 1994 Brittle diabetes lessons for intensive insulin management. Practical Diabetology 13:12-22, 1994.
211. 1994 Small intestine hexose transport in experimental diabetes. Increased transporter mRNA and protein expression in enterocytes. J Clin Invest 93:578-85, 1994.
212. 1993 Hormonal/metabolic regulation of the human GLUT4/muscle-fat facilitative glucose transporter gene in transgenic mice. J Biol Chem 268:9839-46, 1993.
213. 1993 Inhibition of glucose-stimulated insulin release from bTC3 cells and rodent islets by an analog of FK-506. Transplantation 55:186-92, 1993.
214. 1992 Ketoacidosis, HONKC and hypoglycemia Principles of Critical Care Medicine ,McGraw Hill, New York, NY. pp 1966-76, 1992.
215. 1992 Human GLUT4/muscle-fat glucose-transporter gene. Characterization and genetic variation. Diabetes 41:1436-45, 1992.
216. 1992 Expression and regulation of the human GLUT4/muscle-fat facilitative glucose transporter gene in transgenic mice. J Biol Chem 267:11673-6, 1992.
217. 1992 Human intestinal glucose transporter expression and localization of GLUT5. Am J Physiol (Cell Physiol) 31:C795-800, 1992.
218. 1991 Polymorphism in exon 4a of the human GLUT4/muscle-fat facilitative glucose transporter gene detected by SSCP. Nucleic Acids Research 19:4313, 1991.
219. 1991 Cystic fibrosis transmembrane regulator mRNA expression relative to ion-nutrient transport in spontaneously differentiating human intestinal CaCo-2 epithelial cells. J Laboratory and Clinical Med 118:377-81, 1991.
220. 1991 Molecular scanning of the insulin-responsive glucose transporter (GLUT4) gene in NIDDM subjects. Diabetes 40:1712-8, 1991.
221. 1991 Analysis of the gene sequences of the insulin receptor and the insulin-sensitive glucose transporter (GLUT-4 ) in patients with common-type non-insulin-dependent diabetes mellitus. J Clin Invest 88:1323-30, 1991.
222. 1990 Molecular biology of mammalian glucose transporters. Diabetes Care 13:198-208, 1990.
223. 1990 Glucose transporters - molecular structure and function Genes and Gene Products in the Development of Diabetes Mellitus - Basic and Clinical Aspects . Excerpta Medica, Amsterdam. pp. 287-97, 1990
224. 1989 Cloning and characterization of the major insulin-responsive glucose transporter expressed in human skeletal muscle and other insulin-responsive tissues. J Biol Chem 246:7776-9, 1989.
225. 1988 T-cell antigen receptor alpha chain polymorphism in insulin-dependent diabetes. J Autoimmunity 1:389-97, 1988.
226. 1986 The NOD mouse: recessive diabetogenic gene in the major histocompatibility complex. Science 231:733-5, 1986.
227. 1985 Major histocompatibility complex restriction fragment length polymorphisms define three diabetogenic haplotypes in BB and BBN rats. J Exp Med 162:444-58, 1985.
228. 1985 Autoimmune endocrine disease. Vitamins and Hormones 42:253-314, 1985.
229. 1984 Class I, II and III major histocompatibility complex gene polymorphisms in BB rats. Diabetologia 22:77-9, 1984.
230. 1984 Utilization of monoclonal antibody techniques to study Type 1 (insulin dependent) diabetes mellitus Immunology in Diabetes, Kimpton Medical Publications, London. pp 143-57, 1984.
231. 1984 Two genes required for diabetes in BB rats. Evidence from cyclical intercrosses and backcrosses. J Exp Med 159:1629-36, 1984.
232. 1984 Specific class II gene polymorphism in BB rats. Diabetes 33:700-3, 1984.
233. 1983 Lymphocyte abnormalities in the BB rat. Metabolism 32 (Suppl. 1):83-6, 1983.
234. 1982 Disordered cellular immunity in type I diabetes of man and the BB rat. Survey of Immunological Research 1:339-51, 1982.
235. 1982 Monoclonal antibodies in endocrine immunodiagnosis. Clinical Chemistry News 9:19-21, 1982.
236. 1981 Kallikrein-induced uterine contraction independent of kinin formation. Proc Natl Acad Sci USA 78:6154-7, 1981.
237. 1979 The renal kallikrein-kinin system Hormonal Function and the Kidney . Churchill Livingstone, New York. pp 115-45, 1979


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.